Glibclay MP Tablet is a combination antidiabetic medication containing Glibenclamide (5mg), Metformin Hydrochloride (500mg), and Pioglitazone Hydrochloride (15mg). It is formulated to effectively manage Type 2 Diabetes Mellitus (T2DM) by improving insulin sensitivity, reducing glucose production, and enhancing insulin secretion. This triple-drug combination provides a comprehensive approach to controlling blood sugar levels in diabetic patients who require multi-mechanism therapy.
-
Glibenclamide (Sulfonylurea Class): Stimulates the pancreas to release insulin, thereby lowering blood glucose levels.
-
Metformin Hydrochloride (Biguanide Class): Reduces glucose production in the liver and enhances insulin sensitivity, helping muscles absorb and utilize glucose more efficiently.
-
Pioglitazone Hydrochloride (Thiazolidinedione Class): Improves insulin responsiveness in cells, reducing insulin resistance and maintaining better blood sugar control.
Glibclay MP Tablet is beneficial for patients who do not achieve adequate glycemic control with a single or dual therapy. It helps in reducing fasting and postprandial blood glucose levels, thereby preventing complications related to diabetes such as neuropathy, nephropathy, and cardiovascular diseases.
This medication should be used alongside a healthy diet, regular exercise, and lifestyle modifications for optimal results. It is particularly helpful for individuals with obesity-linked diabetes, as Metformin aids in weight management while Pioglitazone improves metabolic function.
Regular monitoring of blood glucose levels and kidney function is essential during the course of treatment. Patients with heart disease, liver impairment, or a history of bladder cancer should use this medication cautiously and only under medical supervision.